Preclinical Study Results of Merrimack’s MM-141 Published in Molecular Cancer Therapeutics

[GlobeNewswire] – CAMBRIDGE, Mass. — Merrimack Pharmaceuticals, Inc. today announced that the manuscript MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity … more

View todays social media effects on MACK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merrimack is hiring next, click here to view